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Abstract
Background: The risk of hepatotoxicity associated with different highly active antiretroviral
therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or
non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully
assessed.
Methods: Retrospective analysis of a prospective cohort of 1,038 HIV-HCV co-infected patients
who commenced a new HAART in the Italian MASTER database. Patients were stratified into naïve
and experienced to antiretroviral therapy before starting the study regimens. Time to grade ≥III
hepatotoxicity (as by ACTG classification) was the primary outcome. Secondary outcome was time
to grade IV hepatotoxicity.
Results: Incidence of grade ≥III hepatotoxicity was 17.71 per 100 patient-years (p-yr) of follow up
in naïve patient group and 8.22 per 100 p-yrs in experienced group (grade IV: 4.13 per 100 p-yrs
and 1.08 per 100 p-yrs, respectively). In the latter group, the only independent factors associated
with shorter time to the event at proportional hazards regression model were: previous liver
transaminase elevations to grade ≥III, higher baseline alanine amino-transferase values, and use of
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a non nucleoside reverse transcriptase inhibitor based regimen. In the naive group, baseline
aspartate transaminase level was associated with the primary outcome.
Conclusion: Use of a single or multiple protease inhibitor based regimen was not associated with
risk of hepatotoxicity in either naïve or experienced patient groups to a statistically significant
extent. A cautious approach with strict monitoring should be applied in HIV-HCV co-infected
experienced patients with previous liver transaminase elevations, higher baseline alanine amino-
transferase values and who receive regimens containing non nucleoside reverse transcriptase
inhibitors.
Background
Highly active anti-retroviral therapy (HAART) is associ-
ated with a number of serious and potentially life-threat-
ening adverse events, including drug-induced liver injury
(so called "hepatotoxicity"). Previous studies demon-
strated the association of hepatotoxicity in HIV-infected
patients treated with HAART, co-infected with hepatitis C
virus (HCV) [1-10]. However, incidence and risk factor
data for liver enzyme elevations in large cohorts of HCV-
HIV co-infected patients are lacking.
Hepatotoxicity has been associated with any currently
used anti-retroviral (ARV) drugs but existing studies fail to
demonstrate a consistent association between a particular
drug or drug class and the development of subsequent
hepatotoxicity, although in a single cohort-study involv-
ing HCV positive and negative patients the recent use of
nevirapine (within 12 weeks of initiating therapy) and the
use of full-dose ritonavir (600 mg bid) have been impli-
cated [9].
It is a general belief that non nucleoside reverse tran-
scriptase inhibitors (NNRTI), especially nevirapine, have
a class effect in terms of abnormal liver enzyme levels, but
an increased rate of serious clinical (symptomatic) hepa-
totoxicity has not been comparatively demonstrated in
general patient populations yet. Moreover, risk of hepato-
toxicity has been shown to be dependent on several con-
comitant conditions, such as viral co-infection, plasma
drug levels, gender and degree of immune damage [11].
Few data are available about the risk of hepatotoxicity
during treatment including low-dose ritonavir co-admin-
istered with a protease inhibitor (so called "boosted" PI
regimens) in comparison with other kinds of regimens. A
study, conducted in patients naïve to therapy [12], sug-
gested that HIV-HCV co-infected patients treated with
lopinavir/ritonavir-based therapy have similar risk of
grade ≥III toxicity when compared with those treated with
nelfinavir-based therapy, but the low number of individ-
uals studied and the rigid inclusion criteria adopted pre-
clude generalizations. Another study, conducted in a
population of both HCV positive and HCV negative
patients [13] compared the incidence of grade ≥III hepa-
totoxicity in patients receiving their first PI-containing reg-
imen, with or without pharmacokinetic enhancement by
low-dose ritonavir, and concluded a similar risk for severe
hepatotoxicity between nelfinavir and lopinavir/ritonavir-
based regimens, although the number of HCV positive
patients was small. Moreover, Meraviglia et al. [14]
reported that the risk of hepatotoxicity on lopinavir/riton-
avir was moderate and influenced by baseline patient
characteristics, including HBV and HCV co-infections.
By contrast, data from a small population of Canadian
HIV-positive subjects co-infected with HBV and/or HCV,
demonstrated that concurrent use of lopinavir/ritonavir
was an independent predictor of grade ≥III alanine
amino-transferase (ALT) elevation [15]. Therefore, com-
parison between different HAART regimens (single-PI,
multiple-PI and NNRTI-based) have given inconsistent
results in term of liver-tolerability in cohorts in which
HIV-HCV co-infected patients are under-represented.
The objective of this paper is to present incidence and risk
factor estimates in one of the largest cohorts of HIV-HCV
co-infected patients presented so far. As patients were
selected for inclusion in the most recent years, it was pos-
sible to assess risk associated with modern antiretroviral
treatment regimens (containing single-PI, multiple-PI and
NNRTI drugs).
Methods
Patients
The study consists of an analysis of a prospective cohort of
HIV-HCV co-infected patients in the Italian MASTER data-
base. The study was conducted in 5 sites: Brescia, Bari,
Pavia, Florence and Turin, in agreement with human
experimentation guidelines of the declaration of Helsinki
and after approval of the Ethic Committee in each partic-
ipating centre. Patients were defined as HCV infected by
the presence of a positive test for HCV antibodies.
All sequential patients who started any HAART regimen,
either PI-or NNRTI-based, from January 2001 to March
2004 have been included in this cohort, provided that a
baseline (BL) determination of CD4+ cell count, HIV
RNA, aspartate amino-transferase (AST) and ALT levelsBMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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within 90 days of commencement of therapy were availa-
ble, and no renal impairment (i.e. creatinine serum level
>2 mg/dl), severe liver function test (LFT) elevation
(either AST or ALT) or bilirubinaemia ≥5 times the upper
limit of normality (ULN) were present. Date of "freezing"
of the data-base for the present analysis was September
2004. Patients have been stratified into treatment experi-
enced (E) and naïve (N) for antiretroviral (ARV) drugs
before starting the study regimens. Patients were asked to
return for clinical and laboratory follow-up (including
liver transaminase levels) after 1 month from baseline and
at least every 3 months thereafter. The ULN for transami-
nase was 45 IU/l for ALT levels and 50 IU/l for AST levels
in all centres.
End points
Any increase by ≥5 × ULN in ALT or AST (i.e., grade III
hepatotoxicity as by AIDS Clinical Trial Group, ACTG,
classification [16]) during the course of HAART was con-
sidered to be the primary end-point. Any increase of ALT
or AST level ≥10 × ULN (grade IV hepatotoxicity) was con-
sidered to be the secondary study end-point [16]. The end-
points were not adjusted for BL elevations to increase the
sensitivity of capture of hepatotoxicity events. To exclude
possible bias, BL LFT elevation was used as a variable in
proportional hazards regression models performed.
Finally, a clinical evaluation of patients who experienced
grade ≥III or IV hepatotoxicity was performed to rule out
that other concomitant causes of LFT elevation were
present (i.e., alcohol abuse, defined as >40 g/day; contin-
uing use of recreational drugs; recent lamivudine/tenofo-
vir discontinuation among HBsAg positive patients; use of
other hepatotoxic drugs; acute infection with other hepa-
totropic micro-organisms).
Statistical analysis
On-treatment (OT) analyses were separately conducted in
N and E groups with grade ≥III hepatotoxicity as primary
outcome measure. Further analyses were conducted using
grade IV hepatotoxicity as a secondary outcome. To
ascribe hepatotoxicity to the current study regimens only,
follow-up was censored at any modification or stopping
of the treatment regimen, or achievement of the study
outcomes, whichever came first.
The following factors assessed at BL were tested at propor-
tional hazards regression models for their possible associ-
ations with occurrence of the study end-points: gender,
age, risk factor for HIV acquisition, nadir CD4+ T-cell
count (defined as the lowest value recorded), chronic HBV
infection (defined as surface antigen positivity), hepatitis
delta virus (HDV) infection (defined as antibody positiv-
ity), ALT and AST serum levels, previous LFT elevation to
≥grade III, HIV-RNA, CD4+ T-cell count, previous use of
interferon, use and length of exposure to dideoxynucleo-
side reverse transcriptase inhibitors (DDX) – i.e. stavu-
dine, didanosine and zalcitabine. Type of HAART in the
study regimens (single PI, multiple PI and NNRTI-based),
and use of DDX, lamivudine (3TC) and tenofovir (TDF)
in the current HAART were also considered. Moreover, to
account for possible effect of immune reconstitution as
risk factor for hepatotoxicity, the CD4+ T-cell count evo-
lution (defined as slope of CD4+ T-cell count since BL
throughout the entire follow-up) was imputed in the
model as a time-dependent covariate (i.e., a variable that
at each follow-up time gives the change in CD4+ T-cell
count since baseline).
All variables with a P-value lower than 0.20 at univariate
analysis were included in multiple proportional hazards
regression model, if clinically meaningful. In all statistical
analyses we stated a significance level P ≤ 0.05. Epi Info
3.2 package (Centers for Diseases Control and Prevention,
Atlanta 4/2/04) and Egret 2.0.31 package (Cytel Software
Corporation, Seattle 1999) were used to perform the
analyses.
Results
Patients
a) Naïve patients
Table 1 shows the main characteristics of the 155 naïve
HIV-HCV co-infected patients enrolled in the study. The
majority of patients acquired HIV infection through
parenteral route (intravenous drug use, IVDU) (67.74%).
Among a total of 32 patients who were prescribed a single
PI-based regimen, 27 (84.38%) received nelfinavir. All 50
patients who were taking multiple PIs were prescribed
ritonavir at low dose (≤200 mg/twice daily), mainly at a
dose of 100 mg/twice daily associated with lopinavir
(84%). Among 73 patients taking NNRTI-based regimens,
42 (57.53%) received efavirenz.
b) Experienced patients
In Table 1, the main characteristics of the 883 experienced
HIV-HCV co-infected patients enrolled in the study are
illustrated. The majority of patients were male (76.67%),
former IVDU (77.46%), and HBsAg negative (93.52%).
Two-hundred and two patients (22.88%) were prescribed
a single PI; 322 (36.47%) multiple PIs and 359 (41.62%)
a NNRTI containing regimen. The single PI most repre-
sented was nelfinavir (72.77%), while in the second
group almost all patients were prescribed low dose riton-
avir (98.75%) plus a full-dose PI, mainly lopinavir
(54.35%). In those receiving a NNRTI, 45.96% received
efavirenz and 54.04% nevirapine.BMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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Table 1: Patient characteristics in naïve and experienced groups
Charactertistic Antiretroviral naïve (N = 155) Antiretroviral experienced (N = 883)
(quantitative) Mean SD Mean SD
Age (years) 38.86 6.47 38.91 5.44
Nadir CD4+ (cells/µl) 185.02 115.79 159.99 131.80
CD4+ T-cell count at baseline (cells/µl) 206.75 133.53 357.88 233.05
HIV-RNA at baseline (copies/ml) 177,480 252,619 53,615 168,410
ALT at baseline (x10 IU/l) 6.94 4.14 7.13 4.42
AST at baseline (x10 IU/l) 6.27 3.88 5.87 3.94
CD4+ T-cell slope (cells/µl) 107.86 116.37 44.30 149.48
Exposure to DDX-drugs at baseline (days) - - 1,288 1,075
(qualitative) N% N %
Gender (male) 113 72.90 677 76.67
Risk factor for HIV acquisition (former IVDU) 105 67.74 684 77.46
HBsAg positivity 15 10.27 55 6.48
HDVAb positivity 4 2.96 25 2.83
Previous grade ≥III LFT elevation 15 9.68 317 35.90
Previous treatment with IFN 7 4.52 72 8.15
Concurrent use of DDX-drugs 50 32.26 526 59.57
Concurrent use of 3TC 138 89.03 618 69.99
Concurrent use of TDF 17 18.97 136 15.40
Treatment group (Single PI) 32 20.64 202 22.88
NFV 27 84.38 147 72.77
IDV 2 6.25 32 15.84
SQV 3 9.37 19 9.41
Others - - 4 1.98
Treatment group (Multiple PI) 50 32.26 322 36.47
LPV/r 42 84 175 54.35
IDV/r 5 10 83 25.78
SQV/r 1 2 48 14.91
Others 2 4 16 4.96
Treatment group (NNRTI) 73 47.10 359 41.62
EFV 42 57.53 165 45.96
NVP 31 42.47 194 54.04
The following abbreviations were used: SD = standard deviation; ALT = alanine amino-transferase, AST = aspartate amino-transferase; DDX = 
dideoxy-nucleoside analogue drugs (i.e., didanosine, stavudine, zalcitabine); IVDU = intra-venous drug use; IFN = interferon; 3TC = lamivudine, TDF 
= tenofovir disoproxil fumarate; PI = protease inhibitor, NFV = nelfinavir, IDV = indinavir, SQV = saquinavir, LPV/r = lopinavir/ritonavir, IDV/r = 
indinavir/ritonavir; SQV/r = saquinavir/ritonavir; NNRTI = non nucleoside reverse transcriptase inhibitor, EFV = efavirenz, NVP = nevirapine.
The following variables were different between drug naive and experienced patients at univariate comparison: nadir CD4+ T-cell count (P: 0.027), 
CD4+ T-cell count at baseline (P < 0.001), HIV-RNA at baseline (P < 0.001), CD4+ T-cell slope (P: <0.001), risk factor for HIV acquisition (P: 
0.009), previous LFT elevation grade ≥III (P < 0.001), concurrent use of DDX-drugs (P < 0.001), concurrent use of 3TC (P < 0.001), use of IDV as 
single PI (P: 0.002), use of LPV/r (P: 0.04) or SQV/r (P: 0.009) as multiple PI, use of EFV as NNRTI (P: 0.016).
CD4+ T-cell slope was available for 146 patients in naïve group and for 844 patients in experienced group; HBsAg status was available for 146 
patients in naive group and for 848 patients in experienced group; HDVAb status was available for 135 patients in naive group and for 833 patients 
in experienced group.BMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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Incidence of relevant hepatotoxicity
a) Naïve patients
A total of 20 cases of grade ≥III hepatotoxicity were
observed (5 on single-PI, 9 on multiple-PI, and 6 on
NNRTI containing regimens), corresponding to an overall
incidence of 17.71 per 100 p-yrs of follow-up. Incidence
of grade ≥III hepatotoxicity was 20.32 per 100 p-yrs
among patients receiving single PI-based regimen, 30.15
per 100 p-yrs among patients receiving multiple PIs and
10.26 per 100 p-yrs in those receiving NNRTI. Additional
90 patients were censored to the follow-up because treat-
ment was changed or stopped for reasons different from
hepatotoxicity (19 on single-PI, 27 on multiple-PI, and 44
on NNRTI containing regimens). Forty-five patients were
still on the initial HAART regimen at the time of "freezing"
the study data base for the analysis. No patient deaths
were recorded during the follow-up.
Incidence of grade IV hepatotoxicity was 4.13 per 100 p-
yrs (corresponding to a total of 5 events), with 0 per 100
p-yrs in single PI group, 12.49 per 100 p-yrs in multiple PI
group and 1.61 per 100 p-yrs in NNRTI group. No signif-
icant differences were reported comparing incidences of
grade ≥III and grade IV hepatotoxicity in patients receiving
nevirapine or efavirenz.
Mean length of observation was 266 days (SD: 263).
Mean number of measurements of transaminase levels
per year was 5.35 (5.59 for single PI group, 6.16 for mul-
tiple PIs group, 4.82 for NNRTI group; t-Student P-value:
0.02).
b) Experienced patients
A total of 58 cases of grade ≥III hepatotoxicity were
observed (6 on single-PI, 21 on multiple-PI, and 31 on
NNRTI containing regimens), corresponding to an overall
incidence of grade ≥III hepatotoxicity of 8.22 per 100 p-
yrs. Incidence of grade ≥III hepatotoxicity was 3.78 per
100 p-yrs in single PI group, 8.05 per 100 p-yrs in multiple
PIs group and 10.82 per 100 p-yrs in NNRTI group. Addi-
tional 583 patients were censored to the follow-up
because treatment was changed or stopped for reasons dif-
ferent from hepatotoxicity (146 on single-PI, 214 on mul-
tiple-PI, and 233 on NNRTI containing regimens). No
patient deaths were recorded during the follow-up. Two-
hundred and forty-two patients were still on the initial
HAART regimen at the time of "freezing" the study data
base for the analysis.
Incidence of grade IV hepatotoxicity was 1.08 per 100 p-
yrs (corresponding to a total of 8 events), with 0.62 per
100 p-yrs in single PI group, 0.74 per 100 p-yrs in multiple
PI group and 1.64 per 100 p-yrs in NNRTI group. As in
naïve patients, there was no significant differences in the
incidences of grade ≥III or grade IV hepatotoxicity
between patients who were prescribed nevirapine and
those who received efavirenz.
Mean length of observation was 292 days (SD: 278).
Mean number of measurements of transaminase level per
year was 4.68 (4.45 for single PI group, 4.81 for multiple
PIs group, 4.69 for NNRTI group; t-Student P-value: 0.26).
Predictors of relevant hepatotoxicity
a) Naïve patients
Figure 1a represents the risk of developing a grade ≥III
hepatotoxicity among naïve patients, stratified by treat-
ment group. At the univariate proportional hazards
regression model, time-to-grade ≥III hepatotoxicity
resulted significantly associated with BL AST level (HR:
1.12, 95%CI = 1.01–1.23; P: 0.029). No significant corre-
lations were found with use of multiple PI versus a single
PI-based regimen (HR: 1.48, 95%CI = 0.49–4.42; P: 0.48)
or with use of a NNRTI versus a single PI-based regimen
(HR: 0.55, 95%CI = 0.17–1.80; P: 0.32).
When time-to-grade IV hepatotoxicity was considered as
dependent variables, none of the factors resulted to be sig-
nificantly associated with hepatotoxicity. Due to the small
number of patients and relatively short follow up, a mul-
tivariable hazards regression model was not performed in
patients who were antiretroviral therapy naïve, either for
the ≥grade III or for the grade IV end-points.
Clinical review did not reveal any concomitant causes for
≥grade III LFT elevations. One patient (an active IVDU),
who was assuming a multiple PI-based regimen, had pre-
viously developed an acute HBV infection that resolved at
the time of hepatotoxicity and another, who was taking a
single PI-based regimen, admitted alcohol abuse although
AST/ALT ratio did not support an acute alcohol hepatitis.
b) Experienced patients
Cumulative risk of time-to-developing a grade ≥III hepa-
totoxicity among experienced patients, stratified by treat-
ment groups, is represented in Figure 1b. Time-to-grade
≥III hepatotoxicity was significantly associated at the uni-
variate proportional hazards regression model with: male
gender (HR: 2.27, 95%CI = 1.03–4.998; P: 0.04), previous
use of IFN (HR: 2.29, 95%CI = 1.16–4.53; P: 0.02), previ-
ous grade ≥III hepatotoxicity (HR: 4.94, 95%CI = 2.81–
8.71; P < 0.001), BL ALT (HR: 1.18 per 10 IU/l higher,
95%CI = 1.12–1.24; P < 0.001), BL AST (HR: 1.11 per 10
IU/l higher, 95%CI = 1.05–1.16; P < 0.001), and NNRTI
versus single PI-based regimens (HR: 2.92, 95%CI = 1.22–
6.99; P: 0.016).
Figure 2 shows all variables with a P-value <0.20 in the
univariate analyses, which were imputed in the multivari-
able regression analysis. A history of previous relevantBMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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Time-to-development of grade ≥III hepatotoxicity among naïve (1a) and experienced (1b) patient groups stratified by type of  antiretroviral treatment regimens prescribed Figure 1
Time-to-development of grade ≥III hepatotoxicity among naïve (1a) and experienced (1b) patient groups 
stratified by type of antiretroviral treatment regimens prescribed. Continuous lines represent patients prescribed 
HIV-1 non nucleoside reverse transcriptase inhibitors; dotted lines represent patients prescribed single HIV-1 protease inhibi-
tor regimens; dashed lines represent patients prescribed multiple HIV-1 protease inhibitor regimens. P: 0.16 for comparison 
across antiretroviral naïve patients prescribed different regimens (see panel 1a); P: 0.027 for comparison across antiretroviral 
experienced patients prescribed different regimens (panel 1b).BMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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hepatotoxicity (HR: 3.05, 95%CI = 1.65–5.63; P < 0.001),
an elevated level of ALT at BL (HR: 1.14 per 10 IU/l higher,
95%CI = 1.08–1.20; P < 0.001) and use of a NNRTI-based
treatment (HR: 2.75, 95%CI = 1.15–6.60; P: 0.02) were
associated with time-to-grade ≥III LFT elevations.
At the univariate proportional hazards regression analyses
performed using occurrence or time-to-grade IV as
dependent variables, none of the factors that were tested
showed significant associations with outcome.
Among patients who had grade ≥III hepatotoxicity events,
those who admitted alcohol abuse were equally distrib-
uted in the 3 treatment groups (1 patient for each single
PI-, multiple PI-and NNRTI-based regimen, the latter con-
taining efavirenz). No other concomitant causes for grade
≥III hepatotoxicity were found.
Results of the multiple proportional hazards regression analysis performed (end-point: grade III LFTs elevation) in experienced  patient group Figure 2
Results of the multiple proportional hazards regression analysis performed (end-point: grade III LFTs eleva-
tion) in experienced patient group. Circles represent hazard ratio; orizontal lines represent 95% confidence interval. The 
following abbreviations were used: IFN = interferon; LFT = liver function test; ALT = alanine amino-transferase, AST = aspar-
tate amino-transferase; DDX = dideoxynucleoside reverse transcriptase inhibitors (i.e., didanosine, stavudine, zalcitabine); PI = 
protease inhibitor; NNRTI = non nucleoside reverse transcriptase inhibitor. Initial models have been run using variables whose 
data were available for all patients. Results for these variables are reported in the present figure. Further separate models have 
been performed imputing variables whose data were not available in some patients, however predictive values of variables 
whose data set was complete did not differ from those obtained through the initial models performed.BMC Infectious Diseases 2005, 5:58 http://www.biomedcentral.com/1471-2334/5/58
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Discussion
This study has a number of strengths but also limitations.
A large number of different drug combinations are used in
the "real-life" setting but the attribution of an episode of
hepatotoxicity to a single ARV agent can be arbitrary. In
assigning a patient to a specific treatment arm, physicians
may be influenced by many considerations. A subjective
evaluation of a high risk of hepatotoxicity may have
resulted in prescription of a regimen with an assumed bet-
ter profile of liver tolerability. Notwithstanding these lim-
itations, observational data reflect the real clinical setting
and this is the widest observational cohort of HIV/HCV
co-infected patients reported so far. In order to be able to
ascribe hepatotoxicity events to ongoing regimen, only a
OT approach may be used, discontinuing follow-up when
any change to HAART occurs.
Multiple PI-based regimens are not, in this analysis, asso-
ciated with a significantly higher risk of developing grade
≥III hepatotoxicity when compared to single PI-based reg-
imens, either among patients naïve or experienced to ARV
drugs. Ritonavir, whose hepatotoxicity is the clearest
defined among PIs, was used rarely at full dosage (1200
mg) in our cohort. When used for pharmacokinetic
enhancement in association with another PI, its dosage
was in most cases ≤400 mg/day. This low-dose of ritonavir
did not appear to influence the liver-toxicity profile of the
regimen, thus confirming the report by Sulkowski et al. in
a small number of HIV-HCV co-infected patients treated
with boosted PI regimens [13].
By contrast, use of NNRTI rather than single PI-based reg-
imens was independently associated, but only among
treatment experienced patients, with a higher risk of grade
≥III hepatotoxicity. This finding suggests that careful man-
agement of these patients, with a strict follow-up should
be performed, especially if other risk factors associated
with hepatotoxicity are present.
Among naïve patients, a higher incidence of severe hepa-
totoxicity and a different pattern of risk factors were
reported than those in experienced patients (including the
use of NNRTI).
It is possible that more prominent immune-reconstitu-
tion occurring in naïve patients than in experienced ones
may have increased the overall hepatotoxicity risk, dilut-
ing the impact exerted by NNRTI as a cofactor for severe
hepatotoxicity. The CD4+ T-cell slope was more pro-
nounced in patients receiving their first line treatment
than in experienced subjects. Moreover, the lack of previ-
ous drug exposure in naïve patients may have led to pre-
scription of drugs whose potential for hepatotoxicity was
less than in the experienced patient cohort, where, due to
HIV drug resistance, less choice is available.
It is however important to recognize possible limitations
of this study. The low number of patients in the naïve
cohort, compared to the experienced cohort, may make
the effect of specific drugs in determining hepatotoxicity
less evident. Moreover, a different frequency in measuring
LFTs, which resulted in more frequent monitoring among
naïve patients taking PI-based regimens, may have led to
an increased detection of toxicity in that group, although
a statistically significant correlation between the fre-
quency of LFT determinations and the risk of hepatotoxic-
ity was not present (data not shown). The low incidence
of grade IV hepatotoxicity events did not allow us to per-
form multivariable analyses. Further studies, with longer
follow-up and conducted in a larger series of patients, are
therefore necessary in this respect. Lastly, several variables
which were not reliably detected in the whole cohort
(especially alcohol abuse) should be further evaluated.
However, the low prevalence of alcohol abusers in those
who had severe hepatotoxicity, which did not cluster in a
specific treatment group, may suggest that alcohol abuse
was not a major confounder.
Conclusion
The risk of severe hepatotoxicity was different among
experienced and naïve patients, with patterns of risk fac-
tors associated with hepatotoxicity being different
between these two groups. Amongst experienced patients,
elevated ALT level at BL, a history of previous LFT eleva-
tion and use of NNRTI-based regimens were independ-
ently associated with the development of grade ≥III
hepatotoxicity. The choice of multiple PI-rather than a
single PI-based regimen did not influence the risk of hepa-
totoxicity to a significant extent. By contrast, a cautious
approach and strict monitoring should be applied in
experienced patients with previous hepatotoxicity events,
high BL ALT values and prescribed NNRTI-containing reg-
imens, who have the greatest risk of severe liver toxicity.
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